Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Pred...
March 30 2017 - 6:59AM
Business Wire
Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine
(NASDAQ:FMI) today announced a collaboration that leverages
Foundation Medicine’s comprehensive genomic profiling and molecular
information solutions to identify predictive biomarkers such as
Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI)
in patients enrolled across clinical trials investigating
Bristol-Myers Squibb’s cancer immunotherapies. Biomarkers can be
used to characterize a tumor and the tumor microenvironment, which
may reveal immune-related mechanisms predictive of how a patient
may respond to immunotherapy.
Cancer immunotherapy works by helping the immune system mount an
anti-cancer response, a process that depends in part on the
recognition of cancer-specific proteins called neoantigens. Higher
levels of tumor mutations have been shown to correlate to the
number of neoantigens, and therefore may help identify patients
more likely to respond to cancer immunotherapies. Foundation
Medicine’s approach utilizing its FoundationOne® assay combines
comprehensive genomic profiling with its advanced and proprietary
algorithms to measure biomarkers, including TMB and MSI, without
the need for whole exome sequencing.
“Translational medicine research is critical to further our
understanding of cancer biology and to identify which patient
populations are most likely to derive benefit from our
Immuno-Oncology agents,” said Fouad Namouni, M.D., head of
Development, Oncology, Bristol-Myers Squibb. “We believe this
collaboration with Foundation Medicine will help us better
understand the relation of genomic approaches to immunotherapy
efficacy across a number of different tumor types and immunotherapy
agents.”
“Cancer immuno-therapy is evolving rapidly, and
biopharmaceutical companies and practicing oncologists alike may
benefit from a reliable, validated, comprehensive view of
mutational burden and genomic alterations to make the most informed
care decisions,” said Melanie Nallicheri, chief business officer
and head, Biopharma for Foundation Medicine. “Our collaboration
with Bristol-Myers Squibb highlights the potential value of our
molecular information platform to the biopharma industry for its
ability to inform, to reduce risk and to accelerate clinical
development in this high growth and highly competitive oncology
field.”
Bristol-Myers Squibb &
Immuno-Oncology: Advancing Oncology Research
At Bristol-Myers Squibb, patients are at the center of
everything we do. Our vision for the future of cancer care is
focused on researching and developing transformational
Immuno-Oncology (I-O) medicines that will raise survival
expectations in hard-to-treat cancers and will change the way
patients live with cancer.
We are leading the scientific understanding of I-O through our
extensive portfolio of investigational and approved agents,
including the first combination of two I-O agents in metastatic
melanoma, and our differentiated clinical development program,
which is studying broad patient populations across more than 35
types of cancers with 13 clinical-stage molecules designed to
target different immune system pathways. Our deep expertise and
innovative clinical trial designs uniquely position us to advance
the science of combinations across multiple tumors and potentially
deliver the next wave of I-O combination regimens with a sense of
urgency. We also continue to pioneer research that will help
facilitate a deeper understanding of the role of immune biomarkers
and inform which patients will benefit most from I-O therapies.
We understand making the promise of I-O a reality for the many
patients who may benefit from these therapies requires not only
innovation on our part but also close collaboration with leading
experts in the field. Our partnerships with academia, government,
advocacy and biotech companies support our collective goal of
providing new treatment options to advance the standards of
clinical practice.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
About Foundation
Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information
company dedicated to a transformation in cancer care in which
treatment is informed by a deep understanding of the genomic
changes that contribute to each patient's unique cancer. The
company offers a full suite of comprehensive genomic profiling
assays to identify the molecular alterations in a patient's cancer
and match them with relevant targeted therapies, immunotherapies
and clinical trials. Foundation Medicine's molecular information
platform aims to improve day-to-day care for patients by serving
the needs of clinicians, academic researchers and drug developers
to help advance the science of molecular medicine in cancer. For
more information, please visit http://www.FoundationMedicine.com or
follow Foundation Medicine on Twitter (@FoundationATCG).
Bristol-Myers Squibb Forward-looking
Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking
statement can be guaranteed. Forward-looking statements in this
press release should be evaluated together with the many
uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2016 in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Foundation Medicine Forward-Looking
Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding a
research and development collaboration between Bristol-Myers-Squibb
and Foundation Medicine , the ability of FoundationOne to measure
tumor mutational burden (TMB) and Microsatellite Instability (MSI),
the conduct of clinical trials by Bristol-Myers-Squibb, and the
utilization of FoundationOne in such clinical trials. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risks that the collaboration does not proceed or does not meet
its objectives of the parties; FoundationOne is not an effective
diagnostic test for measuring TMB or MSI; the clinical trials
anticipated to be conducted by Bristol-Myers Squibb do not take
place or FoundationOne is not utilized in such trials; and the
risks described under the caption "Risk Factors" in Foundation
Medicine's Annual Report on Form 10-K for the year
ended December 31, 2016, filed with the Securities and
Exchange Commission on March 2, 2017, as well as other risks
detailed in Foundation Medicine's subsequent filings with
the Securities and Exchange Commission. All information in
this press release is as of the date of the release,
and Foundation Medicine undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170330005178/en/
Bristol-Myers SquibbMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorSusan Francis,
609-252-4389susan.francis@bms.comorInvestorsTim Power,
609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorFoundation
MedicineMedia:Lee-Ann Murphy,
617-245-3077pr@foundationmedicine.comorInvestors :Kimberly Brown,
617-418-2215ir@foundationmedicine.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024